文献速递心脑血管急症中毒与环境急症

β受体阻滞剂用于可卡因相关胸痛结局的荟萃分析

Outcomes of beta blocker use in cocaine-associated chest pain: a meta-analysis.
PubMed 文献 · Emerg Med J · 2018-06-19
一句话结论在可卡因相关胸痛患者中,β受体阻滞剂使用与不增加心肌梗死及全因死亡风险相关(OR 1.36,95%CI 0.68-2.75;OR 0.68,95%CI 0.26-1.79)。

该系统评价与荟萃分析检索MEDLINE和EMBASE至2016年9月,纳入5项比较β受体阻滞剂与不使用β受体阻滞剂的可卡因相关胸痛研究,共1794例受试者。主要结局非致死性心肌梗死无显著差异(OR 1.36,95%CI 0.68-2.75;p=0.39),全因死亡也无显著差异(OR 0.68,95%CI 0.26-1.79;p=0.43)。结论认为β受体阻滞剂使用似乎不增加心肌梗死或全因死亡风险。

要点

  • 可卡因相关胸痛患者使用β受体阻滞剂与不使用者相比,非致死性心肌梗死风险无显著差异(OR 1.36,95%CI 0.68-2.75;p=0.39)。
  • 可卡因相关胸痛患者使用β受体阻滞剂与不使用者相比,全因死亡风险无显著差异(OR 0.68,95%CI 0.26-1.79;p=0.43)。
  • 共纳入5项研究、1794例受试者,采用随机效应模型进行定量合成,异质性用Q和I2统计量评估。
  • 作者结论:在表现为急性胸痛且潜在可卡因使用的患者中,β受体阻滞剂使用似乎不增加心肌梗死或全因死亡风险。

适用人群与场景

  • 表现为急性胸痛且潜在可卡因使用的患者(可卡因相关胸痛,CACP)。

研究设计与关键结果

  • 研究类型:系统评价与荟萃分析;纳入5项研究,共1794例受试者。
  • 干预与对照:β受体阻滞剂使用 vs 不使用β受体阻滞剂。
  • 主要结局非致死性心肌梗死:OR 1.36(95%CI 0.68-2.75;p=0.39),两组无显著差异。
  • 全因死亡:OR 0.68(95%CI 0.26-1.79;p=0.43),两组无显著差异。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在表现为急性胸痛且潜在可卡因使用的患者中,β受体阻滞剂使用似乎不增加心肌梗死或全因死亡风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Beta blockers (β-blockers) remain a standard therapy in the early treatment of acute coronary syndromes. However, β-blocker therapy in patients with cocaine-associated chest pain (CACP) continues to be an area of debate due to the potential risk of unopposed α-adrenergic stimulation and coronary vasospasm. Therefore, we performed a systematic review and meta-analysis of available studies to compare outcomes of β-blocker versus no β-blocker use among patients with CACP.

METHODS: We searched the MEDLINE and EMBASE databases through September 2016 using the keywords 'beta blocker', 'cocaine' and commonly used β-blockers ('atenolol', 'bisoprolol', 'carvedilol', 'esmolol', 'metoprolol' and 'propranolol') to identify studies evaluating β-blocker use among patients with CACP. We specifically focused on studies comparing outcomes between β-blocker versus no β-blocker usage in patients with CACP. Studies without a comparison between β-blocker and no β-blocker use were excluded. Outcomes of interest included non-fatal myocardial infarction (MI) and all-cause mortality. Quantitative data synthesis was performed using a random-effects model and heterogeneity was assessed using Q and I2statistics.

RESULTS: A total of five studies evaluating 1794 subjects were included. Overall, there was no significant difference on MI in patients with CACP on β-blocker versus no β-blocker (OR 1.36, 95% CI 0.68 to 2.75; p=0.39). Similarly, there was no significant difference in all-cause mortality in patients on β-blocker versus no β-blocker (OR 0.68, 95% CI 0.26 to 1.79; p=0.43).

CONCLUSIONS: In patients presenting with acute chest pain and underlying cocaine, β-blocker use does not appear to be associated with an increased risk of MI or all-cause mortality.

来源:Emerg Med J,查看原文。版权归原作者所有。

参考来源

  1. Pham D, Addison D, Kayani W, et al. Outcomes of beta blocker use in cocaine-associated chest pain: a meta-analysis. Emerg Med J. 2018. PMID: 29921621. doi:10.1136/emermed-2017-207065

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。